Johnson & Johnson has decided to withdraw its Linx device for gastroesophageal reflux disease (GERD) from certain international markets after reassessing demand. The magnetic implant — designed to reinforce the lower esophageal sphincter — will, however, remain available in the U.S. The company insists safety and efficacy are unchanged, framing the move as part of a broader portfolio realignment. Which countries are losing access, and what does this signal for the future of GERD innovation?
J&J exits Linx esophageal reflux business in some countries (MedTech Dive)
0